文献速递细菌感染、耐药与抗菌药物

达巴万星对比标准疗法治疗金黄色葡萄球菌菌血症的经济学结局:DOTS随机临床试验

Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial.
PubMed 文献 · Clin Infect Dis · 2026-09-17

基于DOTS随机试验中200例复杂性金黄色葡萄球菌菌血症成人患者,从随机化时点比较达巴万星与标准疗法的医疗资源使用与费用。达巴万星组住院天数与抗生素使用天数更少,其较高的药物费用被住院及OPAT费用下降所抵消,净费用更低,注射吸毒患者节省更明显。

要点

  • 达巴万星组SAB相关住院平均少2.2天,抗生素使用少24.4天。
  • 居家OPAT情景下达巴万星净费用低5931美元,门诊OPAT情景低4574美元。
  • 注射吸毒患者中达巴万星节省约22000美元。

核心结论

  • 平均而言,住院照护减少与OPAT减少带来的节省完全抵消了达巴万星较高的药物费用。
  • 在注射吸毒患者中,达巴万星的节省更为明显。

研究设计与样本

  • DOTS随机临床试验的经济学分析,纳入200例复杂性金黄色葡萄球菌菌血症成人患者,随机接受两剂达巴万星或标准疗法抗生素。
  • 费用估算从随机化开始,使用试验中的住院与抗生素日期,达巴万星及多数抗生素按仿制药定价,并采用Medicare支付费率估算居家或门诊OPAT情景。

主要发现

  • 达巴万星组SAB相关住院日平均少2.2天(95%CI:-5.3至1.3),抗生素使用天数平均少24.4天(95%CI:-29.0至-19.9)。
  • SAB相关住院平均费用在达巴万星组低5805美元(95%CI:-14,311至3390)。
  • 抗生素药物费用在达巴万星组高2343美元(95%CI:1728至3027)。
  • 居家OPAT情景下达巴万星OPAT费用低2469美元(95%CI:-2913至-1970),门诊OPAT情景低1112美元(95%CI:-1289至-914)。

关键数值与推荐

  • 居家OPAT情景下SAB相关净费用达巴万星组低5931美元(95%CI:-14,660至3004)。
  • 门诊OPAT情景下SAB相关净费用达巴万星组低4574美元(95%CI:-13,312至4335)。
  • 注射吸毒患者中达巴万星节省约22000美元。

临床怎么用

  • 对复杂性金黄色葡萄球菌菌血症患者,达巴万星可减少住院与抗生素使用天数,并通过降低OPAT费用抵消其较高药价。
  • 在注射吸毒患者中,达巴万星的经济学优势可能更突出,可结合OPAT模式选择用药。

局限性

  • 费用基于仿制药定价与Medicare支付费率估算,可能受不同支付体系影响。
  • 经济结局来自DOTS试验人群,外推至其他患者群体需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The DOTS trial demonstrated similar clinical outcomes among 200 adults with complicated Staphylococcus aureus bacteremia (SAB) randomized to two doses of dalbavancin or standard-therapy antibiotics after initial clearance. We aimed to determine whether the higher cost of dalbavancin is offset through reductions in medical resource use. METHODS: We used dates for hospitalizations and antibiotics from the trial starting from randomization. Antibiotic costs were based on generic pricing for dalbavancin and most other antibiotics. Medicare payment rates were used to estimate costs for scenarios representing home-based or clinic-based outpatient antibiotic therapy (OPAT). RESULTS: On average, patients randomized to dalbavancin spent 2.2 fewer SAB-related days in the hospital (95%CI: -5.3 to 1.3) and received antibiotics on 24.4 fewer days (95%CI: -29.0 to -19.9). Mean inpatient costs for SAB-related admissions were lower by $5805 (95%CI: -14,311 to 3390) in the dalbavancin group. Antibiotic drug costs were $2343 higher (95%CI: 1728 to 3027), but OPAT costs were lower with dalbavancin by $2469 (95% CI: -2913 to -1970) in the home-based scenario and $1112 (95% CI: -1289 to -914) in the clinic-based scenario. Net costs for SAB-related care were $5931 lower (95%CI: -14,660 to 3004) and $4574 lower (95%CI: -13,312 to 4335) with dalbavancin versus standard-therapy with home-based and clinic-based OPAT, respectively. Among patients with injection drug use (IDU), savings with dalbavancin were approximately $22,000. CONCLUSIONS: On average, savings from reduced inpatient care and less OPAT fully offset the higher cost of dalbavancin in patients with SAB. Savings were greater in patients with IDU.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Reed SD, Li Y, Turner NA, et al. Economic Outcomes of Dalbavancin versus Standard Therapy in Staphylococcus aureus Bacteremia in the DOTS Randomized Clinical Trial. Clin Infect Dis. 2026. PMID: 42752824. doi:10.1093/cid/ciag567

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。